xml: <clinical_study>
    <!-- This xml conforms to an XML Schema at:
      https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
    <required_header>
      <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
      <link_text>Link to the current ClinicalTrials.gov record.</link_text>
      <url>https://clinicaltrials.gov/ct2/show/NCT06030999</url>
    </required_header>
    <id_info>
      <org_study_id>23-SM-08-WL-001</org_study_id>
      <nct_id>NCT06030999</nct_id>
    </id_info>
    <brief_title>The Prevention And Treatment On Obesity And Weight Management By Oral Supplementation Of Probiotics And Prebiotics</brief_title>
    <official_title>Three Arms, Randomized, Double-blind Controlled Trial Of Prevention And Treatment On Obesity And Weight Management By Oral Supplementation Of Probiotics And Prebiotics</official_title>
    <sponsors>
      <lead_sponsor>
        <agency>Shenzhen Precision Health Food Technology Co. Ltd.,</agency>
        <agency_class>Other</agency_class>
      </lead_sponsor>
    </sponsors>
    <source>Shenzhen Precision Health Food Technology Co. Ltd.,</source>
    <oversight_info>
      <has_dmc>No</has_dmc>
      <is_fda_regulated_drug>No</is_fda_regulated_drug>
      <is_fda_regulated_device>No</is_fda_regulated_device>
    </oversight_info>
    <brief_summary>
      <textblock>
        The goal of this interventional study is to test whether consumption of Wonderlab probiotics&#xD;
        with prebiotics could improve obesity and overweight in Chinese people who are aged 25-45 and&#xD;
        overweight. The main question it aims to answer is:&#xD;
  &#xD;
        - whether the weight of participants can be lost after 10 weeks' intervention&#xD;
  &#xD;
        150 participants will be randomized into 3 study groups (50 each group) in the two study&#xD;
        sites, who will consume assigned product according to instructions for 10 weeks. Three site&#xD;
        visits will be made for each participant and all relevant clinical data will be captured and&#xD;
        recorded into CTMS(Clinical Trial Management System) for statistical analysis.&#xD;
  &#xD;
        Researchers will compare the three groups to conclude whether the Wonderlab study product can&#xD;
        improve obesity and overweight over placebo product.&#xD;
      </textblock>
    </brief_summary>
    <overall_status>Recruiting</overall_status>
    <start_date type="Anticipated">September 25, 2023</start_date>
    <completion_date type="Anticipated">December 15, 2023</completion_date>
    <primary_completion_date type="Anticipated">December 2, 2023</primary_completion_date>
    <phase>N/A</phase>
    <study_type>Interventional</study_type>
    <has_expanded_access>No</has_expanded_access>
    <study_design_info>
      <allocation>Randomized</allocation>
      <intervention_model>Parallel Assignment</intervention_model>
      <primary_purpose>Supportive Care</primary_purpose>
      <masking>Double (Participant, Investigator)</masking>
    </study_design_info>
    <primary_outcome>
      <measure>Change of Weight</measure>
      <time_frame>baseline day 0, day 70</time_frame>
      <description>Change of Weight in Kg by Inbody S10 from baseline to 10 weeks</description>
    </primary_outcome>
    <secondary_outcome>
      <measure>Blood lipids - Total Cholesterol Level</measure>
      <time_frame>baseline day 0, day 35, day 70</time_frame>
      <description>Blood lipids - Total Cholesterol level of blood test in mmol/L and range of 0.56-17mmol/L for each visit interval</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Blood Sugar Level</measure>
      <time_frame>baseline day 0, day 35, day 70</time_frame>
      <description>Blood sugar level of blood test in mmol/L and range of 3.9-6.1mmol/L</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Blood hormone - Leptin level</measure>
      <time_frame>baseline day 0, day 35, day 70</time_frame>
      <description>Blood hormone - Leptin level of blood test in ng/mL and range 0.5-15.2ng/mL</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Blood hormone - Adiponectin level</measure>
      <time_frame>baseline day 0, day 35, day 70</time_frame>
      <description>Blood hormone - Adiponectin level of blood test in ug/mL and range of 2-37ug/mL</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Blood inflammation</measure>
      <time_frame>baseline day 0, day 35, day 70</time_frame>
      <description>Blood inflammation (Zonulin, ApoB-48, hsCRP, LPS, sCD14, IL-6, MCP-1, Angptl4)</description>
    </secondary_outcome>
    <number_of_arms>3</number_of_arms>
    <enrollment type="Anticipated">150</enrollment>
    <condition>Overweight and Obesity</condition>
    <arm_group>
      <arm_group_label>Study product A (Wonderlab wonder4shape)</arm_group_label>
      <arm_group_type>Active Comparator</arm_group_type>
      <description>2g/bottle, containing the following probiotics total dosage 2.0*1010 CFU:&#xD;
  CECT7527, CECT7528, CECT7529&#xD;
  Maltodextrin&#xD;
  Lactobacillus acidophilus&#xD;
  Fructose oligosaccharides&#xD;
  Grapefruit, Lemon and Apple powder</description>
    </arm_group>
    <arm_group>
      <arm_group_label>Study product B (Wonderlab wonder4shape)</arm_group_label>
      <arm_group_type>Active Comparator</arm_group_type>
      <description>2g/bottle, containing the following probiotics total dosage 1.0*1010 CFU:&#xD;
  Maltodextrin&#xD;
  Lactobacillus acidophilus</description>
    </arm_group>
    <arm_group>
      <arm_group_label>Study product C (placebo)</arm_group_label>
      <arm_group_type>Placebo Comparator</arm_group_type>
      <description>2g/bottle, containing the following ingredients:&#xD;
  Maltodextrin&#xD;
  Grapefruit powder&#xD;
  Lemon powder</description>
    </arm_group>
    <intervention>
      <intervention_type>Dietary Supplement</intervention_type>
      <intervention_name>Study product A (Wonderlab wonder4shape)</intervention_name>
      <description>Participants in this arm need to consume one bottle (2g) of this product once a day for 10 weeks</description>
      <arm_group_label>Study product A (Wonderlab wonder4shape)</arm_group_label>
    </intervention>
    <intervention>
      <intervention_type>Dietary Supplement</intervention_type>
      <intervention_name>Study product B (Wonderlab wonder4shape)</intervention_name>
      <description>Participants in this arm need to consume one bottle (2g) of this product once a day for 10 weeks</description>
      <arm_group_label>Study product B (Wonderlab wonder4shape)</arm_group_label>
    </intervention>
    <intervention>
      <intervention_type>Dietary Supplement</intervention_type>
      <intervention_name>Study product C (placebo)</intervention_name>
      <description>Participants in this arm need to consume one bottle (2g) of this product once a day for 10 weeks</description>
      <arm_group_label>Study product C (placebo)</arm_group_label>
    </intervention>
    <eligibility>
      <criteria>
        <textblock>
          Inclusion Criteria:&#xD;
  &#xD;
            -  Chinese males or females, age between 25-45;&#xD;
  &#xD;
            -  Overweight population: BMI 24-27.9 &amp; obesity population: BMI &gt;=28;&#xD;
  &#xD;
            -  Blood lipids in high potential risks but without medication:TG &gt; 5mol/L or LDL &gt;= 3.4&#xD;
               mmol/L or TC &gt;= 5.2 mmol/L.&#xD;
  &#xD;
            -  Understand the test procedure, read, and sign an appropriate Informed Consent Form&#xD;
               indicating their willingness to participate;&#xD;
  &#xD;
            -  Agree to avoid medication treatment for weight management, including blood lipids and&#xD;
               sugar control.&#xD;
  &#xD;
          Exclusion Criteria:&#xD;
  &#xD;
            -  Have used any medication for weight management at least one month before this study.&#xD;
  &#xD;
            -  Subject having done plastic surgery for weight management.&#xD;
  &#xD;
            -  Be involved in any aspect of test administration, i.e., evaluating or overseeing&#xD;
               activities related to product.&#xD;
  &#xD;
            -  Have participated in any clinical study involving the test sites within the previous 6&#xD;
               months, or is subject participating in any clinical study concurrently.&#xD;
  &#xD;
            -  Have a history of any type of metabolic syndrome, including but not limited to any&#xD;
               type of diabetes, obesity and heart disease.&#xD;
  &#xD;
            -  Have a history of any disease or the presence of health condition on the study sites&#xD;
               that the Investigator feels would interfere with the study.&#xD;
  &#xD;
            -  Be taking antihistamines (&gt; 3x/week) or anti-inflammatory (&gt; 8x/week) on a regular&#xD;
               basis, or has the subject taken systemic or topical steroidal medications within 4&#xD;
               weeks of study enrolment.&#xD;
  &#xD;
            -  Have any of the following conditions or factors that the investigator believes may&#xD;
               affect the response of the skin or the interpretation of the test results, including,&#xD;
               but not limited to, pregnancy, lactation and hepatitis.&#xD;
  &#xD;
            -  Have any cuts/abrasions on the test site at baseline.&#xD;
  &#xD;
            -  The subject is an employee of sponsor or the site conducting the study.&#xD;
        </textblock>
      </criteria>
      <gender>All</gender>
      <minimum_age>25 Years</minimum_age>
      <maximum_age>45 Years</maximum_age>
      <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
    </eligibility>
    <overall_official>
      <last_name>Hongwei Guo, MD</last_name>
      <role>Principal Investigator</role>
      <affiliation>Shanghai Fudan University, School of Public Health</affiliation>
    </overall_official>
    <overall_official>
      <last_name>Weixing Wang, MD</last_name>
      <role>Principal Investigator</role>
      <affiliation>Shanghai Jiao Tong University School of Medicine</affiliation>
    </overall_official>
    <overall_contact>
      <last_name>Charlie Zhang, MD</last_name>
      <phone>+8613901981272</phone>
      <email>charlie.zhang@sprimmedical.com</email>
    </overall_contact>
    <location>
      <facility>
        <name>SPRIM Central Lab</name>
        <address>
          <city>Shanghai</city>
          <state>Shanghai</state>
          <country>China</country>
        </address>
      </facility>
      <status>Recruiting</status>
      <contact>
        <last_name>Melody Hou</last_name>
        <phone>+8613917849430</phone>
        <email>melody.hou@sprimmedical.com</email>
      </contact>
    </location>
    <location>
      <facility>
        <name>Ligang Hospital</name>
        <address>
          <city>Jinhua</city>
          <state>Zhejiang</state>
          <country>China</country>
        </address>
      </facility>
      <status>Recruiting</status>
      <contact>
        <last_name>Charlie BC Zhang, MD</last_name>
        <phone>+8613901981272</phone>
        <email>charlie.zhang@sprimmedical.com</email>
      </contact>
    </location>
    <location_countries>
      <country>China</country>
    </location_countries>
    <reference>
      <citation>Aoun A, Darwish F, Hamod N. The Influence of the Gut Microbiome on Obesity in Adults and the Role of Probiotics, Prebiotics, and Synbiotics for Weight Loss. Prev Nutr Food Sci. 2020 Jun 30;25(2):113-123. doi: 10.3746/pnf.2020.25.2.113.</citation>
      <PMID>32676461</PMID>
    </reference>
    <reference>
      <citation>Guirro M, Costa A, Gual-Grau A, Herrero P, Torrell H, Canela N, Arola L. Effects from diet-induced gut microbiota dysbiosis and obesity can be ameliorated by fecal microbiota transplantation: A multiomics approach. PLoS One. 2019 Sep 23;14(9):e0218143. doi: 10.1371/journal.pone.0218143. eCollection 2019.</citation>
      <PMID>31545802</PMID>
    </reference>
    <reference>
      <citation>Gill VJS, Soni S, Shringarpure M, Anusheel, Bhardwaj S, Yadav NK, Patel A, Patel A. Gut Microbiota Interventions for the Management of Obesity: A Literature Review. Cureus. 2022 Sep 19;14(9):e29317. doi: 10.7759/cureus.29317. eCollection 2022 Sep.</citation>
      <PMID>36161997</PMID>
    </reference>
    <reference>
      <citation>Hill C, Guarner F, Reid G, Gibson GR, Merenstein DJ, Pot B, Morelli L, Canani RB, Flint HJ, Salminen S, Calder PC, Sanders ME. Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol. 2014 Aug;11(8):506-14. doi: 10.1038/nrgastro.2014.66. Epub 2014 Jun 10.</citation>
      <PMID>24912386</PMID>
    </reference>
    <reference>
      <citation>Gibson GR, Hutkins R, Sanders ME, Prescott SL, Reimer RA, Salminen SJ, Scott K, Stanton C, Swanson KS, Cani PD, Verbeke K, Reid G. Expert consensus document: The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics. Nat Rev Gastroenterol Hepatol. 2017 Aug;14(8):491-502. doi: 10.1038/nrgastro.2017.75. Epub 2017 Jun 14.</citation>
      <PMID>28611480</PMID>
    </reference>
    <reference>
      <citation>Swanson KS, Gibson GR, Hutkins R, Reimer RA, Reid G, Verbeke K, Scott KP, Holscher HD, Azad MB, Delzenne NM, Sanders ME. The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of synbiotics. Nat Rev Gastroenterol Hepatol. 2020 Nov;17(11):687-701. doi: 10.1038/s41575-020-0344-2. Epub 2020 Aug 21.</citation>
      <PMID>32826966</PMID>
    </reference>
    <reference>
      <citation>Arora T, Sharma R. Fermentation potential of the gut microbiome: implications for energy homeostasis and weight management. Nutr Rev. 2011 Feb;69(2):99-106. doi: 10.1111/j.1753-4887.2010.00365.x.</citation>
      <PMID>21294743</PMID>
    </reference>
    <reference>
      <citation>Lee HY, Park JH, Seok SH, Baek MW, Kim DJ, Lee KE, Paek KS, Lee Y, Park JH. Human originated bacteria, Lactobacillus rhamnosus PL60, produce conjugated linoleic acid and show anti-obesity effects in diet-induced obese mice. Biochim Biophys Acta. 2006 Jul;1761(7):736-44. doi: 10.1016/j.bbalip.2006.05.007. Epub 2006 May 20.</citation>
      <PMID>16807088</PMID>
    </reference>
    <reference>
      <citation>Martin FP, Wang Y, Sprenger N, Yap IK, Lundstedt T, Lek P, Rezzi S, Ramadan Z, van Bladeren P, Fay LB, Kochhar S, Lindon JC, Holmes E, Nicholson JK. Probiotic modulation of symbiotic gut microbial-host metabolic interactions in a humanized microbiome mouse model. Mol Syst Biol. 2008;4:157. doi: 10.1038/msb4100190. Epub 2008 Jan 15.</citation>
      <PMID>18197175</PMID>
    </reference>
    <reference>
      <citation>Guazzelli Marques C, de Piano Ganen A, Zaccaro de Barros A, Thomatieli Dos Santos RV, Dos Santos Quaresma MVL. Weight loss probiotic supplementation effect in overweight and obesity subjects: A review. Clin Nutr. 2020 Mar;39(3):694-704. doi: 10.1016/j.clnu.2019.03.034. Epub 2019 Apr 3.</citation>
      <PMID>30987812</PMID>
    </reference>
    <reference>
      <citation>Bosch M, Fuentes MC, Audivert S, Bonachera MA, Peiro S, Cune J. Lactobacillus plantarum CECT 7527, 7528 and 7529: probiotic candidates to reduce cholesterol levels. J Sci Food Agric. 2014 Mar 15;94(4):803-9. doi: 10.1002/jsfa.6467. Epub 2013 Dec 4.</citation>
      <PMID>24186773</PMID>
    </reference>
    <reference>
      <citation>Kim GB, Yi SH, Lee BH. Purification and characterization of three different types of bile salt hydrolases from Bifidobacterium strains. J Dairy Sci. 2004 Feb;87(2):258-66. doi: 10.3168/jds.S0022-0302(04)73164-1.</citation>
      <PMID>14762068</PMID>
    </reference>
    <reference>
      <citation>Begley M, Hill C, Gahan CG. Bile salt hydrolase activity in probiotics. Appl Environ Microbiol. 2006 Mar;72(3):1729-38. doi: 10.1128/AEM.72.3.1729-1738.2006. No abstract available.</citation>
      <PMID>16517616</PMID>
    </reference>
    <reference>
      <citation>Verhoog S, Taneri PE, Roa Diaz ZM, Marques-Vidal P, Troup JP, Bally L, Franco OH, Glisic M, Muka T. Dietary Factors and Modulation of Bacteria Strains of Akkermansia muciniphila and Faecalibacterium prausnitzii: A Systematic Review. Nutrients. 2019 Jul 11;11(7):1565. doi: 10.3390/nu11071565.</citation>
      <PMID>31336737</PMID>
    </reference>
    <reference>
      <citation>Hills RD Jr, Pontefract BA, Mishcon HR, Black CA, Sutton SC, Theberge CR. Gut Microbiome: Profound Implications for Diet and Disease. Nutrients. 2019 Jul 16;11(7):1613. doi: 10.3390/nu11071613.</citation>
      <PMID>31315227</PMID>
    </reference>
    <verification_date>September 2023</verification_date>
    <study_first_submitted>September 3, 2023</study_first_submitted>
    <study_first_submitted_qc>September 3, 2023</study_first_submitted_qc>
    <study_first_posted type="Actual">September 11, 2023</study_first_posted>
    <last_update_submitted>September 3, 2023</last_update_submitted>
    <last_update_submitted_qc>September 3, 2023</last_update_submitted_qc>
    <last_update_posted type="Actual">September 11, 2023</last_update_posted>
    <responsible_party>
      <responsible_party_type>Sponsor</responsible_party_type>
    </responsible_party>
    <keyword>Probiotics</keyword>
    <keyword>Prebiotics</keyword>
    <keyword>Wonderlab</keyword>
    <condition_browse>
      <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
      <mesh_term>Obesity</mesh_term>
      <mesh_term>Overweight</mesh_term>
    </condition_browse>
    <patient_data>
      <sharing_ipd>No</sharing_ipd>
    </patient_data>
    <!-- Results have not yet been posted for this study                                          -->
  </clinical_study>
  
  
text: download date: ClinicalTrials.gov processed this data on September 20, 2023
  link text: Link to the current ClinicalTrials.gov record.
  url: https://clinicaltrials.gov/ct2/show/NCT06030999
  org study id: 23-SM-08-WL-001
  nct id: NCT06030999
  lead sponsor: 
  has dmc: No
  is fda regulated drug: No
  is fda regulated device: No
  The goal of this interventional study is to test whether consumption of Wonderlab probiotics
        with prebiotics could improve obesity and overweight in Chinese people who are aged 25-45 and
        overweight. The main question it aims to answer is:
  
        - whether the weight of participants can be lost after 10 weeks' intervention
  
        150 participants will be randomized into 3 study groups (50 each group) in the two study
        sites, who will consume assigned product according to instructions for 10 weeks. Three site
        visits will be made for each participant and all relevant clinical data will be captured and
        recorded into CTMS(Clinical Trial Management System) for statistical analysis.
  
        Researchers will compare the three groups to conclude whether the Wonderlab study product can
        improve obesity and overweight over placebo product.
  allocation: Randomized
  intervention model: Parallel Assignment
  primary purpose: Supportive Care
  masking: Double (Participant, Investigator)
  measure: Change of Weight
  time frame: baseline day 0, day 70
  description: Change of Weight in Kg by Inbody S10 from baseline to 10 weeks
  measure: Blood lipids - Total Cholesterol Level
  time frame: baseline day 0, day 35, day 70
  description: Blood lipids - Total Cholesterol level of blood test in mmol/L and range of 0.56-17mmol/L for each visit interval
  measure: Blood Sugar Level
  time frame: baseline day 0, day 35, day 70
  description: Blood sugar level of blood test in mmol/L and range of 3.9-6.1mmol/L
  measure: Blood hormone - Leptin level
  time frame: baseline day 0, day 35, day 70
  description: Blood hormone - Leptin level of blood test in ng/mL and range 0.5-15.2ng/mL
  measure: Blood hormone - Adiponectin level
  time frame: baseline day 0, day 35, day 70
  description: Blood hormone - Adiponectin level of blood test in ug/mL and range of 2-37ug/mL
  measure: Blood inflammation
  time frame: baseline day 0, day 35, day 70
  description: Blood inflammation (Zonulin, ApoB-48, hsCRP, LPS, sCD14, IL-6, MCP-1, Angptl4)
  arm group label: Study product A (Wonderlab wonder4shape)
  arm group type: Active Comparator
  description: 2g/bottle, containing the following probiotics total dosage 2.0*1010 CFU:
  CECT7527, CECT7528, CECT7529
  Maltodextrin
  Lactobacillus acidophilus
  Fructose oligosaccharides
  Grapefruit, Lemon and Apple powder
  arm group label: Study product B (Wonderlab wonder4shape)
  arm group type: Active Comparator
  description: 2g/bottle, containing the following probiotics total dosage 1.0*1010 CFU:
  Maltodextrin
  Lactobacillus acidophilus
  arm group label: Study product C (placebo)
  arm group type: Placebo Comparator
  description: 2g/bottle, containing the following ingredients:
  Maltodextrin
  Grapefruit powder
  Lemon powder
  intervention type: Dietary Supplement
  intervention name: Study product A (Wonderlab wonder4shape)
  description: Participants in this arm need to consume one bottle (2g) of this product once a day for 10 weeks
  arm group label: Study product A (Wonderlab wonder4shape)
  intervention type: Dietary Supplement
  intervention name: Study product B (Wonderlab wonder4shape)
  description: Participants in this arm need to consume one bottle (2g) of this product once a day for 10 weeks
  arm group label: Study product B (Wonderlab wonder4shape)
  intervention type: Dietary Supplement
  intervention name: Study product C (placebo)
  description: Participants in this arm need to consume one bottle (2g) of this product once a day for 10 weeks
  arm group label: Study product C (placebo)
  criteria: 
  gender: All
  minimum age: 25 Years
  maximum age: 45 Years
  healthy volunteers: Accepts Healthy Volunteers
  last name: Hongwei Guo, MD
  role: Principal Investigator
  affiliation: Shanghai Fudan University, School of Public Health
  last name: Weixing Wang, MD
  role: Principal Investigator
  affiliation: Shanghai Jiao Tong University School of Medicine
  last name: Charlie Zhang, MD
  phone: +8613901981272
  email: charlie.zhang@sprimmedical.com
  facility: 
  status: Recruiting
  contact: 
  facility: 
  status: Recruiting
  contact: 
  country: China
  citation: Aoun A, Darwish F, Hamod N. The Influence of the Gut Microbiome on Obesity in Adults and the Role of Probiotics, Prebiotics, and Synbiotics for Weight Loss. Prev Nutr Food Sci. 2020 Jun 30;25(2):113-123. doi: 10.3746/pnf.2020.25.2.113.
  PMID: 32676461
  citation: Guirro M, Costa A, Gual-Grau A, Herrero P, Torrell H, Canela N, Arola L. Effects from diet-induced gut microbiota dysbiosis and obesity can be ameliorated by fecal microbiota transplantation: A multiomics approach. PLoS One. 2019 Sep 23;14(9):e0218143. doi: 10.1371/journal.pone.0218143. eCollection 2019.
  PMID: 31545802
  citation: Gill VJS, Soni S, Shringarpure M, Anusheel, Bhardwaj S, Yadav NK, Patel A, Patel A. Gut Microbiota Interventions for the Management of Obesity: A Literature Review. Cureus. 2022 Sep 19;14(9):e29317. doi: 10.7759/cureus.29317. eCollection 2022 Sep.
  PMID: 36161997
  citation: Hill C, Guarner F, Reid G, Gibson GR, Merenstein DJ, Pot B, Morelli L, Canani RB, Flint HJ, Salminen S, Calder PC, Sanders ME. Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol. 2014 Aug;11(8):506-14. doi: 10.1038/nrgastro.2014.66. Epub 2014 Jun 10.
  PMID: 24912386
  citation: Gibson GR, Hutkins R, Sanders ME, Prescott SL, Reimer RA, Salminen SJ, Scott K, Stanton C, Swanson KS, Cani PD, Verbeke K, Reid G. Expert consensus document: The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics. Nat Rev Gastroenterol Hepatol. 2017 Aug;14(8):491-502. doi: 10.1038/nrgastro.2017.75. Epub 2017 Jun 14.
  PMID: 28611480
  citation: Swanson KS, Gibson GR, Hutkins R, Reimer RA, Reid G, Verbeke K, Scott KP, Holscher HD, Azad MB, Delzenne NM, Sanders ME. The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of synbiotics. Nat Rev Gastroenterol Hepatol. 2020 Nov;17(11):687-701. doi: 10.1038/s41575-020-0344-2. Epub 2020 Aug 21.
  PMID: 32826966
  citation: Arora T, Sharma R. Fermentation potential of the gut microbiome: implications for energy homeostasis and weight management. Nutr Rev. 2011 Feb;69(2):99-106. doi: 10.1111/j.1753-4887.2010.00365.x.
  PMID: 21294743
  citation: Lee HY, Park JH, Seok SH, Baek MW, Kim DJ, Lee KE, Paek KS, Lee Y, Park JH. Human originated bacteria, Lactobacillus rhamnosus PL60, produce conjugated linoleic acid and show anti-obesity effects in diet-induced obese mice. Biochim Biophys Acta. 2006 Jul;1761(7):736-44. doi: 10.1016/j.bbalip.2006.05.007. Epub 2006 May 20.
  PMID: 16807088
  citation: Martin FP, Wang Y, Sprenger N, Yap IK, Lundstedt T, Lek P, Rezzi S, Ramadan Z, van Bladeren P, Fay LB, Kochhar S, Lindon JC, Holmes E, Nicholson JK. Probiotic modulation of symbiotic gut microbial-host metabolic interactions in a humanized microbiome mouse model. Mol Syst Biol. 2008;4:157. doi: 10.1038/msb4100190. Epub 2008 Jan 15.
  PMID: 18197175
  citation: Guazzelli Marques C, de Piano Ganen A, Zaccaro de Barros A, Thomatieli Dos Santos RV, Dos Santos Quaresma MVL. Weight loss probiotic supplementation effect in overweight and obesity subjects: A review. Clin Nutr. 2020 Mar;39(3):694-704. doi: 10.1016/j.clnu.2019.03.034. Epub 2019 Apr 3.
  PMID: 30987812
  citation: Bosch M, Fuentes MC, Audivert S, Bonachera MA, Peiro S, Cune J. Lactobacillus plantarum CECT 7527, 7528 and 7529: probiotic candidates to reduce cholesterol levels. J Sci Food Agric. 2014 Mar 15;94(4):803-9. doi: 10.1002/jsfa.6467. Epub 2013 Dec 4.
  PMID: 24186773
  citation: Kim GB, Yi SH, Lee BH. Purification and characterization of three different types of bile salt hydrolases from Bifidobacterium strains. J Dairy Sci. 2004 Feb;87(2):258-66. doi: 10.3168/jds.S0022-0302(04)73164-1.
  PMID: 14762068
  citation: Begley M, Hill C, Gahan CG. Bile salt hydrolase activity in probiotics. Appl Environ Microbiol. 2006 Mar;72(3):1729-38. doi: 10.1128/AEM.72.3.1729-1738.2006. No abstract available.
  PMID: 16517616
  citation: Verhoog S, Taneri PE, Roa Diaz ZM, Marques-Vidal P, Troup JP, Bally L, Franco OH, Glisic M, Muka T. Dietary Factors and Modulation of Bacteria Strains of Akkermansia muciniphila and Faecalibacterium prausnitzii: A Systematic Review. Nutrients. 2019 Jul 11;11(7):1565. doi: 10.3390/nu11071565.
  PMID: 31336737
  citation: Hills RD Jr, Pontefract BA, Mishcon HR, Black CA, Sutton SC, Theberge CR. Gut Microbiome: Profound Implications for Diet and Disease. Nutrients. 2019 Jul 16;11(7):1613. doi: 10.3390/nu11071613.
  PMID: 31315227
  responsible party type: Sponsor
  mesh term: Obesity
  mesh term: Overweight
  sharing ipd: No